Second Sight Medical Products (EYES) Given Daily News Sentiment Score of 0.05

Media headlines about Second Sight Medical Products (NASDAQ:EYES) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Second Sight Medical Products earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned media headlines about the medical device company an impact score of 46.0597279002689 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Second Sight Medical Products traded up $0.06, hitting $1.61, during mid-day trading on Friday, Marketbeat Ratings reports. 283,506 shares of the company’s stock traded hands, compared to its average volume of 190,812. Second Sight Medical Products has a fifty-two week low of $0.90 and a fifty-two week high of $2.58. The company has a market capitalization of $103.97 million, a price-to-earnings ratio of -2.73 and a beta of 3.08.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings results on Tuesday, August 7th. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. Second Sight Medical Products had a negative return on equity of 432.45% and a negative net margin of 418.82%. The business had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.21 million. sell-side analysts expect that Second Sight Medical Products will post -0.58 EPS for the current year.

Several research firms have recently commented on EYES. HC Wainwright set a $5.00 price objective on Second Sight Medical Products and gave the company a “buy” rating in a report on Wednesday. Zacks Investment Research downgraded Second Sight Medical Products from a “buy” rating to a “hold” rating in a report on Tuesday, July 17th. Finally, ValuEngine raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

In other Second Sight Medical Products news, VP Edward David Randolph sold 16,023 shares of the stock in a transaction on Friday, June 1st. The stock was sold at an average price of $1.96, for a total transaction of $31,405.08. Following the transaction, the vice president now owns 16,045 shares in the company, valued at approximately $31,448.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gregg Williams acquired 25,355 shares of the stock in a transaction on Friday, June 1st. The shares were purchased at an average price of $1.99 per share, for a total transaction of $50,456.45. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 324,803 shares of company stock valued at $584,633 and have sold 27,213 shares valued at $54,164. Company insiders own 34.70% of the company’s stock.

About Second Sight Medical Products

Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Recommended Story: Relative Strength Index

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply